EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Peptidomimetic PROTACs as Potential Degraders of 3-Chymotrypsin-like Protease of SARS-CoV-2

Chao Wei, Yuhua Li iD, Lina Guo, Zhiyu Shao, Hua Diao

International Journal of Molecular Sciences · 21.04.2025 · 26 (8) · 3903

DOI: 10.3390/ijms26083903 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.04.2025. Verfasst von Chao Wei und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Chemical Engineering, Donghua University, Shanghai 201620, China. Hauptthemen laut MEDLINE: Peptidomimetics, SARS-CoV-2, Coronavirus 3C Proteases, Antiviral Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

3CL protease (3CLpro), a key enzyme of SARS-CoV-2 replication, is one of the most selective targets of antivirals, as no homologous protease has been recognized in the human body. As proteolysis-targeting chimeras (PROTACs) are superior to traditional inhibitors, based on the reported cereblon (CRBN) ligands thalidomide and lenalidomide, 3CLpro ligands of peptidomimetic inhibitors, and suitable linkers, we aimed to develop novel PROTACs that may trigger efficient intracellular 3CLpro degradation through a balance of hydrophilicity and lipophilicity. In brief, we designed and synthesized 5 PROTAC molecules. The 3CLpro degradation efficiency of the PROTACs was assayed in stable SARS-CoV-2 3CLpro expression HEK293 cell models and evaluated by Western blot. All compounds showed prominent 3CLpro degradation activity with tolerable HEK293 cytotoxicity. The most prominent PROTAC compounds, 15 and 16, have DC50 values of approximately 1 µM, and Dmax of 89.3% and 75% respectively, indicating good potential for further application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PeptidomimeticsSARS-CoV-2Coronavirus 3C ProteasesAntiviral AgentsHumansHEK293 CellsProteolysisCOVID-19 Drug TreatmentProtease InhibitorsCOVID-19Ubiquitin-Protein LigasesProteolysis Targeting Chimera

Stichwörter der Autor:innen

3CL proteaselenalidomide derivativesproteolysis-targeting chimerastargeted protein degradationthalidomide derivatives

Substanzen

PeptidomimeticsCoronavirus 3C ProteasesAntiviral Agents3C-like proteinase, SARS-CoV-2Protease InhibitorsUbiquitin-Protein LigasesProteolysis Targeting Chimera

Autor:innen und Institutionen

  • College of Chemistry and Chemical Engineering, Donghua University, Shanghai 201620, China.
  • NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Ph…

ORCID-Profile: Yuhua Li

Förderung

  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Wei, C., Li, Y., Guo, L., Shao, Z., & Diao, H. (2025). Development of Peptidomimetic PROTACs as Potential Degraders of 3-Chymotrypsin-like Protease of SARS-CoV-2. International Journal of Molecular Sciences, 26(8), 3903. https://doi.org/10.3390/ijms26083903

Vancouver

Wei C, Li Y, Guo L, Shao Z, Diao H. Development of Peptidomimetic PROTACs as Potential Degraders of 3-Chymotrypsin-like Protease of SARS-CoV-2. International Journal of Molecular Sciences. 2025;26(8):3903. doi:10.3390/ijms26083903

BibTeX
@article{Wei2025,
  author = {Wei, Chao and Li, Yuhua and Guo, Lina and Shao, Zhiyu and Diao, Hua},
  title = {Development of Peptidomimetic PROTACs as Potential Degraders of 3-Chymotrypsin-like Protease of SARS-CoV-2},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {8},
  pages = {3903},
  doi = {10.3390/ijms26083903}
}
Kostenlos starten →